source
- Novo’s CagriSema shows over 20% weight loss at low doses in Phase 3 trialNovo Nordisk presented new Phase 3 data on its experimental obesity combo CagriSema at ObesityWeek 2026. The low‑dose arm (1 mg and 1.7 mg weekly) achieved average weight reductions of about 21% a…
- Helus Pharma’s Phase 3 trial shows strong depression benefit but safety concerns emergeHelus Pharma reported that its deuterated psilocin candidate HLP003 achieved the primary endpoint in a Phase 3 trial for major depressive disorder when added to patients' existing antidepressants.…